Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Incyte Corp 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 USA

P: 302-498-6700

Description:

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.

Key Statistics

Overview:

Market Capitalization, $K 15,104,526
Shares Outstanding, K 220,891
Annual Sales, $ 2,667 M
Annual Net Income, $ -295,700 K
Last Quarter Sales, $ 812,990 K
Last Quarter Net Income, $ 181,740 K
60-Month Beta 0.76
% of Insider Shareholders 15.80%
% of Institutional Shareholders 86.93%
Float, K 185,990
% Float 84.20%

Growth:

1-Year Return -15.75%
3-Year Return 6.43%
5-Year Return -32.97%
5-Year Revenue Growth 253.79%
5-Year Earnings Growth -2,220.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.18 on 11/02/21
Next Earnings Date N/A
Earnings Per Share ttm 2.88
EPS Growth vs. Prev Qtr 53.85%
EPS Growth vs. Prev Year 3,233.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/01/00

INCY Ratios

Ratio
Price/Earnings ttm 23.17
Price/Earnings forward 164.56
Price/Earnings to Growth 0.70
Return-on-Equity % 22.27%
Return-on-Assets % 16.60%
Profit Margin % -11.09
Net Margin % -51.17
Debt/Equity 0.01
Price/Sales 5.53
Price/Cash Flow N/A
Price/Book 4.68
Book Value/Share 14.25
Interest Coverage -106.01
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar